Developer docs
API playgroundTry for free, no card

Search company profiles

Solid Biosciences

Full company profile

uuid0000bwa

Namestring
Solid Biosciences
Legal namestring
Solid Biosciences Inc.
Websiteurl
solidbio.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Solid Biosciences is a clinical-stage precision genetic medicine company developing a portfolio of AAV (adeno-associated virus) gene therapies targeting rare neuromuscular and cardiac diseases. Founded in 2013 by Ilan and Annie Ganot after their son's Duchenne muscular dystrophy diagnosis, the company is headquartered in Charlestown, Massachusetts, trades on NASDAQ as SLDB, and has 51-100 employees. Its lead clinical program, SGT-003, is an investigational next-generation microdystrophin gene therapy using the proprietary POLARIS-101™ (AAV-SLB101) capsid platform, currently in Phase 1/2 (INSPIRE DUCHENNE, 40 participants dosed) and Phase 3 (IMPACT DUCHENNE, initiated May 2026) trials for Duchenne muscular dystrophy. Two additional clinical programs are advancing: SGT-212 (Friedreich's ataxia, Phase 1b FALCON trial initiated Jan 2026), which uses a first-in-class dual-route administration approach combining stereotactic MRI-guided cerebellar infusion with intravenous delivery, and SGT-501 (CPVT, Phase 1b Artemis trial), which delivers a functional CASQ2 gene to heart muscle. Three preclinical cardiac programs (SGT-601, SGT-401, SGT-701) round out the pipeline.

The company's core technology platform is the rationally designed POLARIS-101™ AAV capsid, which demonstrates enhanced muscle transduction and reduced liver biodistribution compared to first-generation capsids, supported by a broader capsid library with 50+ licensing and evaluation agreements. Manufacturing relies on a proprietary transient transfection-based gene therapy production process with in-house process development capabilities. The company pursues a pre-revenue clinical-stage business model with future revenue expected from gene therapy product sales (comparable DMD therapies priced at ~$3.2M per treatment) and non-exclusive licensing of capsid technology to other gene therapy developers. Distribution is structured through clinical trial sites globally (US, Canada, Italy, UK, Australia), with planned specialty treatment center commercialization upon regulatory approval.

The company is led by President and CEO Bo Cumbo (former Sarepta CCO), CFO Kevin Tan, CMO Gabriel Brooks (former Pfizer Rare Cardiovascular TA Head), and Chairman Ian Smith (former Vertex CFO/COO). Capital structure is anchored by repeat institutional investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, with cumulative private placement funding exceeding $880M since 2022. The most recent $240M placement in March 2026 extended cash runway into H1 2028, supporting advancement of three clinical-stage programs and expansion of the capsid platform through licensing partnerships.

Short descriptiontext

Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy (SGT-003, Phase 3), Friedreich's ataxia (SGT-212, Phase 1b), and CPVT (SGT-501, Phase 1b), leveraging its proprietary POLARIS-101™ next-generation capsid platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, rare disease therapeutics, AAV capsid platform, neuromuscular disease treatments, precision genetic medicine
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Therapy Biologics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage company. Future revenue expected from commercialization of gene therapy candidates following regulatory approval. Gene therapies for rare diseases typically command premium pricing (e.g., $3.2M for comparable DMD therapies).

investors.solidbio.com
2Licensing and Technology Access
TypeLicensing Royalties
Description

Non-exclusive licensing of proprietary capsid technology (AAV-SLB101/POLARIS-101™) to other gene therapy developers. Generates revenue through licensing fees and potential milestone payments.

solidbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1No commercial products available for pricing
ModelOtherBilling cadenceOne time/ perpetual license
Notes

Company is in clinical development stage with no approved products. Pricing would apply to gene therapy candidates upon regulatory approval. Comparable therapies (e.g., Sarepta's Elevidys at $3.2M) suggest premium pricing for DMD gene therapies.

biospace.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1POLARIS-101™
Description

Next-generation AAV capsid technology (AAV-SLB101) for muscle-targeted gene therapy with enhanced transduction and reduced liver biodistribution.

solidbio.com
Core offering1 text field

Solid Biosciences is a clinical-stage precision genetic medicine company developing AAV gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (SGT-003), Friedreich's ataxia (SGT-212), and CPVT (SGT-501). The company leverages its proprietary POLARIS-101 (AAV-SLB101) next-generation capsid platform to deliver therapeutic genes and out-licenses the capsid technology to other gene therapy developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 60% mean microdystrophin expression in muscle fibers in Phase 1/2 trial participants
+4 more records
Product overview1 text field

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases. The company's pipeline includes multiple clinical-stage programs: SGT-003 (Duchenne muscular dystrophy, Phase 1/2 and Phase 3), SGT-212 (Friedreich's ataxia, Phase 1b), and SGT-501 (CPVT, Phase 1b), along with preclinical cardiac programs (SGT-601, SGT-401, SGT-701). The company has developed POLARIS-101™ (AAV-SLB101), a next-generation muscle-tropic capsid platform that is being out-licensed to partners and is the delivery vehicle for its lead clinical programs. The technology platform includes a broader capsid library with over 50 evaluation agreements.

Product and service7 records
1SGT-003
CategoryGene Therapy - Duchenne Muscular Dystrophy
Description

Investigational next-generation microdystrophin gene therapy for Duchenne muscular dystrophy using the POLARIS-101 (AAV-SLB101) capsid for improved muscle targeting and reduced liver biodistribution. Currently in Phase 1/2 INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE trials.

2SGT-212
CategoryGene Therapy - Friedreich's Ataxia
Description

First-in-class dual-route gene therapy for Friedreich's ataxia delivering a functional frataxin (FXN) gene via intradentate nucleus infusion followed by intravenous administration to address neurological, cardiac, and systemic manifestations. Currently in Phase 1b FALCON trial.

3SGT-501
CategoryGene Therapy - CPVT
Description

Gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) caused by RYR2 mutations, delivering a functional CASQ2 gene to heart muscle cells to address abnormal calcium signaling. In Phase 1b Artemis trial.

4SGT-601
CategoryGene Therapy - Dilated Cardiomyopathy
Description

Preclinical gene therapy candidate for TNNT2-mediated dilated cardiomyopathy that delivers the TNNT2 gene to address cardiac dysfunction caused by TNNT2 mutations.

5SGT-401
CategoryGene Therapy - Dilated Cardiomyopathy
Description

Preclinical gene therapy candidate for BAG3-mediated dilated cardiomyopathy.

6SGT-701
CategoryGene Therapy - Dilated Cardiomyopathy
Description

Preclinical gene therapy candidate for RBM20-mediated dilated cardiomyopathy.

7POLARIS-101 (AAV-SLB101) Capsid Platform
CategoryCapsid Technology Platform
Description

Next-generation rationally designed AAV capsid technology with enhanced muscle tropism, reduced liver biodistribution, and robust transduction. Available for non-exclusive out-licensing to gene therapy developers; serves as the delivery vehicle for Solid's lead clinical programs.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-02
Description

Co-marketing agreement combining Solid's POLARIS-101™ next-generation capsid technology with NanoMosaic's FDA AMT-designated Tessie™ platform for multi-omic capsid and transgene analytics. Partnership aims to provide gene therapy developers with integrated access to advanced delivery and measurement technologies.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-17
Description

Non-exclusive worldwide licensing agreement for use of proprietary next-generation capsid AAV-SLB101 (POLARIS-101™) in gene therapy manufacturing. The agreement supports further development of AAV-SLB101, which has demonstrated positive safety and efficacy signals in clinical and preclinical studies.

3ICS Maugeri
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Silvia Priori's lab at ICS Maugeri in Pavia, Italy. Solid in-licensed the therapeutic approach for SGT-501 (CASQ2 gene therapy for CPVT) based on pioneering research from Dr. Priori's team.

solidbio.com
4Friedreich's Ataxia Research Alliance (FARA)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Ongoing partnership with FARA for Friedreich's ataxia clinical program development. FARA provides guidance and support shaping the clinical program. Collaboration helps advance clinically meaningful therapies for the FA community.

solidbio.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership with SADS Foundation for CPVT community engagement. Plans to host community webinars to educate patients and families about investigational gene therapy SGT-501 and upcoming clinical trials.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Charitable partnership with PPMD as part of Solid's community engagement. PPMD is a leading Duchenne advocacy organization.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Charitable partnership with Cure Duchenne as part of Solid's community engagement initiatives.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Charitable partnership and conference participation with MDA. Solid presents clinical data at MDA Clinical & Scientific Conference.

9Cooperative International Neuromuscular Research Group (CINRG)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

PPMD partnership with CINRG to support expanded Duchenne Natural History Study (eDNHS), involving participation from multiple pharmaceutical companies, academic institutions, and clinical sites worldwide.

prnewswire.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration with Mayo Clinic for cardiac gene therapy programs. Listed as partner on pipeline page with six undisclosed targets.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sarepta Therapeutics is the leading developer of gene therapies for Duchenne muscular dystrophy, with Elevidys (delandistrogene moxeparvovec) already approved and generating commercial revenue. It is Solid's most direct competitor in DMD gene therapy and the benchmark for both efficacy and pricing in the indication.

TypeDirect peer
Description

Regenxbio is an AAV gene therapy platform company that licenses its NAV capsid technology and develops internal rare disease programs including ABBV-RGX-314 (wet AMD) and RGX-121 (Hunter syndrome). It directly competes with Solid's POLARIS-101 capsid licensing model and has a similar DMD partnership history.

TypeDirect peer
Description

uniQure is an AAV gene therapy company focused on rare diseases with a clinical-stage DMD program and an approved hemophilia B therapy (Hemgenix). It directly competes with Solid in neuromuscular and AAV-mediated rare disease gene therapy development and shares a similar target customer base of rare disease specialists.

TypeDirect peer
Description

Krystal Biotech is a commercial-stage gene therapy company (Vyjuvek for DEB) with a pipeline including an AAV-based DMD program. It is comparable to Solid in its rare disease gene therapy focus and shares the same regulatory pathway and rare disease commercial model.

TypeDirect peer
Description

Lexeo Therapeutics is a clinical-stage AAV gene therapy company with a strong focus on cardiac genetic diseases, including programs in Friedreich's ataxia cardiomyopathy and other inherited cardiomyopathies. It is one of Solid's closest direct peers in the cardiac AAV gene therapy space.

TypeDirect peer
Description

Tenaya Therapeutics is a clinical-stage genetic medicines company focused on cardiac diseases, developing both gene therapies and gene editing approaches for inherited cardiomyopathies. It is comparable to Solid's SGT-501 and preclinical cardiac programs (SGT-601/401/701) in target indication and modality.

TypeDirect peer
Description

4D Molecular Therapeutics is a clinical-stage AAV gene therapy company that uses proprietary capsid engineering to develop targeted therapies for rare diseases including DMD and cardiac indications. Its Therapeutic Vector Evolution platform is comparable to Solid's POLARIS-101 capsid library.

TypeDirect peer
Description

Rocket Pharmaceuticals is a clinical-stage AAV gene therapy company developing treatments for rare diseases including Danon disease and LAD-I. It shares Solid's model of targeting ultra-rare monogenic diseases with AAV-delivered gene therapy and operates in a similar commercialization context via specialty treatment centers.

TypeBroad incumbent
Description

Pfizer is a large pharmaceutical company with a significant rare disease gene therapy franchise, including Beqvez (approved hemophilia B therapy) and a discontinued DMD gene therapy program. Its rare cardiovascular TA leadership also overlaps with Solid's cardiac focus, and Solid's CMO Gabriel Brooks joined from Pfizer.

TypeBroad incumbent
Description

BioMarin Pharmaceutical is an established rare disease biopharmaceutical company with a commercial gene therapy (Roctavian for hemophilia A) and an extensive rare disease portfolio. It is comparable to Solid in its focus on ultra-rare genetic disease therapeutics with premium pricing and specialty distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solid Biosciences

Gene Therapy Biologicssolidbio.com

Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy (SGT-003, Phase 3), Friedreich's ataxia (SGT-212, Phase 1b), and CPVT (SGT-501, Phase 1b), leveraging its proprietary POLARIS-101™ next-generation capsid platform.

What Solid Biosciences does

Solid Biosciences is a clinical-stage precision genetic medicine company developing a portfolio of AAV (adeno-associated virus) gene therapies targeting rare neuromuscular and cardiac diseases. Founded in 2013 by Ilan and Annie Ganot after their son's Duchenne muscular dystrophy diagnosis, the company is headquartered in Charlestown, Massachusetts, trades on NASDAQ as SLDB, and has 51-100 employees. Its lead clinical program, SGT-003, is an investigational next-generation microdystrophin gene therapy using the proprietary POLARIS-101™ (AAV-SLB101) capsid platform, currently in Phase 1/2 (INSPIRE DUCHENNE, 40 participants dosed) and Phase 3 (IMPACT DUCHENNE, initiated May 2026) trials for Duchenne muscular dystrophy. Two additional clinical programs are advancing: SGT-212 (Friedreich's ataxia, Phase 1b FALCON trial initiated Jan 2026), which uses a first-in-class dual-route administration approach combining stereotactic MRI-guided cerebellar infusion with intravenous delivery, and SGT-501 (CPVT, Phase 1b Artemis trial), which delivers a functional CASQ2 gene to heart muscle. Three preclinical cardiac programs (SGT-601, SGT-401, SGT-701) round out the pipeline.

The company's core technology platform is the rationally designed POLARIS-101™ AAV capsid, which demonstrates enhanced muscle transduction and reduced liver biodistribution compared to first-generation capsids, supported by a broader capsid library with 50+ licensing and evaluation agreements. Manufacturing relies on a proprietary transient transfection-based gene therapy production process with in-house process development capabilities. The company pursues a pre-revenue clinical-stage business model with future revenue expected from gene therapy product sales (comparable DMD therapies priced at ~$3.2M per treatment) and non-exclusive licensing of capsid technology to other gene therapy developers. Distribution is structured through clinical trial sites globally (US, Canada, Italy, UK, Australia), with planned specialty treatment center commercialization upon regulatory approval.

The company is led by President and CEO Bo Cumbo (former Sarepta CCO), CFO Kevin Tan, CMO Gabriel Brooks (former Pfizer Rare Cardiovascular TA Head), and Chairman Ian Smith (former Vertex CFO/COO). Capital structure is anchored by repeat institutional investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, with cumulative private placement funding exceeding $880M since 2022. The most recent $240M placement in March 2026 extended cash runway into H1 2028, supporting advancement of three clinical-stage programs and expansion of the capsid platform through licensing partnerships.

Solid Biosciences firmographics

Firmographics
Name
Solid Biosciences
Legal name
Solid Biosciences Inc.
Website
https://solidbio.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy (SGT-003, Phase 3), Friedreich's ataxia (SGT-212, Phase 1b), and CPVT (SGT-501, Phase 1b), leveraging its proprietary POLARIS-101™ next-generation capsid platform.
Ownership category
akta.pro rank

Solid Biosciences industry classification

Industry
Product category
Gene Therapy Biologics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Rare disease therapeutics
  • AAV capsid platform
  • Neuromuscular disease treatments
  • Precision genetic medicine

Where Solid Biosciences is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Solid Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Product Sales: Pre-revenue clinical stage company. Future revenue expected from commercialization of gene therapy candidates following regulatory approval. Gene therapies for rare diseases typically command premium pricing (e.g., $3.2M for comparable DMD therapies).
  2. Licensing and Technology Access: Non-exclusive licensing of proprietary capsid technology (AAV-SLB101/POLARIS-101™) to other gene therapy developers. Generates revenue through licensing fees and potential milestone payments.

Pricing tiers

ModelBillingPrice
OtherOne time/ perpetual licenseNo commercial products available for pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Solid Biosciences product offering

Product offering

Core offering

Solid Biosciences is a clinical-stage precision genetic medicine company developing AAV gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (SGT-003), Friedreich's ataxia (SGT-212), and CPVT (SGT-501). The company leverages its proprietary POLARIS-101 (AAV-SLB101) next-generation capsid platform to deliver therapeutic genes and out-licenses the capsid technology to other gene therapy developers.

Product overview

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases. The company's pipeline includes multiple clinical-stage programs: SGT-003 (Duchenne muscular dystrophy, Phase 1/2 and Phase 3), SGT-212 (Friedreich's ataxia, Phase 1b), and SGT-501 (CPVT, Phase 1b), along with preclinical cardiac programs (SGT-601, SGT-401, SGT-701). The company has developed POLARIS-101™ (AAV-SLB101), a next-generation muscle-tropic capsid platform that is being out-licensed to partners and is the delivery vehicle for its lead clinical programs. The technology platform includes a broader capsid library with over 50 evaluation agreements.

Differentiator

Problem solved

Functional benefit

Brands

  • POLARIS-101™: Next-generation AAV capsid technology (AAV-SLB101) for muscle-targeted gene therapy with enhanced transduction and reduced liver biodistribution.

Products and services

  • SGT-003 Investigational next-generation microdystrophin gene therapy for Duchenne muscular dystrophy using the POLARIS-101 (AAV-SLB101) capsid for improved muscle targeting and reduced liver biodistribution. Currently in Phase 1/2 INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE trials.
  • SGT-212 First-in-class dual-route gene therapy for Friedreich's ataxia delivering a functional frataxin (FXN) gene via intradentate nucleus infusion followed by intravenous administration to address neurological, cardiac, and systemic manifestations. Currently in Phase 1b FALCON trial.
  • SGT-501 Gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) caused by RYR2 mutations, delivering a functional CASQ2 gene to heart muscle cells to address abnormal calcium signaling. In Phase 1b Artemis trial.
  • SGT-601 Preclinical gene therapy candidate for TNNT2-mediated dilated cardiomyopathy that delivers the TNNT2 gene to address cardiac dysfunction caused by TNNT2 mutations.
  • SGT-401 Preclinical gene therapy candidate for BAG3-mediated dilated cardiomyopathy.
  • SGT-701 Preclinical gene therapy candidate for RBM20-mediated dilated cardiomyopathy.
  • POLARIS-101 (AAV-SLB101) Capsid Platform Next-generation rationally designed AAV capsid technology with enhanced muscle tropism, reduced liver biodistribution, and robust transduction. Available for non-exclusive out-licensing to gene therapy developers; serves as the delivery vehicle for Solid's lead clinical programs.

Quantifiable outcome

  • 60% mean microdystrophin expression in muscle fibers in Phase 1/2 trial participants
  • +4 more outcomes

Companies that use Solid Biosciences

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Solid Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Solid Biosciences partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered strategic and core.

  • NanoMosaicstrategicTechnology or Integration · 2 June 2026Co-marketing agreement combining Solid's POLARIS-101™ next-generation capsid technology with NanoMosaic's FDA AMT-designated Tessie™ platform for multi-omic capsid and transgene analytics. Partnership aims to provide gene therapy developers with integrated access to advanced delivery and measurement technologies.
  • Andelyn BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 17 November 2025Non-exclusive worldwide licensing agreement for use of proprietary next-generation capsid AAV-SLB101 (POLARIS-101™) in gene therapy manufacturing. The agreement supports further development of AAV-SLB101, which has demonstrated positive safety and efficacy signals in clinical and preclinical studies.
  • ICS MaugeristrategicStrategic or Co-development PartnerResearch collaboration with Dr. Silvia Priori's lab at ICS Maugeri in Pavia, Italy. Solid in-licensed the therapeutic approach for SGT-501 (CASQ2 gene therapy for CPVT) based on pioneering research from Dr. Priori's team.
  • Friedreich's Ataxia Research Alliance (FARA)strategicStrategic or Co-development PartnerOngoing partnership with FARA for Friedreich's ataxia clinical program development. FARA provides guidance and support shaping the clinical program. Collaboration helps advance clinically meaningful therapies for the FA community.
  • SADS FoundationstrategicStrategic or Co-development PartnerPartnership with SADS Foundation for CPVT community engagement. Plans to host community webinars to educate patients and families about investigational gene therapy SGT-501 and upcoming clinical trials.
  • Parent Project Muscular Dystrophy (PPMD)strategicStrategic or Co-development PartnerCharitable partnership with PPMD as part of Solid's community engagement. PPMD is a leading Duchenne advocacy organization.
  • Cure DuchennestrategicStrategic or Co-development PartnerCharitable partnership with Cure Duchenne as part of Solid's community engagement initiatives.
  • Muscular Dystrophy Association (MDA)strategicStrategic or Co-development PartnerCharitable partnership and conference participation with MDA. Solid presents clinical data at MDA Clinical & Scientific Conference.
  • Cooperative International Neuromuscular Research Group (CINRG)strategicStrategic or Co-development PartnerPPMD partnership with CINRG to support expanded Duchenne Natural History Study (eDNHS), involving participation from multiple pharmaceutical companies, academic institutions, and clinical sites worldwide.
  • Mayo ClinicstrategicStrategic or Co-development PartnerCollaboration with Mayo Clinic for cardiac gene therapy programs. Listed as partner on pipeline page with six undisclosed targets.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Solid Biosciences competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Sarepta Therapeutics is the leading developer of gene therapies for Duchenne muscular dystrophy, with Elevidys (delandistrogene moxeparvovec) already approved and generating commercial revenue. It is Solid's most direct competitor in DMD gene therapy and the benchmark for both efficacy and pricing in the indication.
  • Regenxbio: Regenxbio is an AAV gene therapy platform company that licenses its NAV capsid technology and develops internal rare disease programs including ABBV-RGX-314 (wet AMD) and RGX-121 (Hunter syndrome). It directly competes with Solid's POLARIS-101 capsid licensing model and has a similar DMD partnership history.
  • uniQure: uniQure is an AAV gene therapy company focused on rare diseases with a clinical-stage DMD program and an approved hemophilia B therapy (Hemgenix). It directly competes with Solid in neuromuscular and AAV-mediated rare disease gene therapy development and shares a similar target customer base of rare disease specialists.
  • Krystal Biotech: Krystal Biotech is a commercial-stage gene therapy company (Vyjuvek for DEB) with a pipeline including an AAV-based DMD program. It is comparable to Solid in its rare disease gene therapy focus and shares the same regulatory pathway and rare disease commercial model.
  • Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage AAV gene therapy company with a strong focus on cardiac genetic diseases, including programs in Friedreich's ataxia cardiomyopathy and other inherited cardiomyopathies. It is one of Solid's closest direct peers in the cardiac AAV gene therapy space.
  • Tenaya Therapeutics: Tenaya Therapeutics is a clinical-stage genetic medicines company focused on cardiac diseases, developing both gene therapies and gene editing approaches for inherited cardiomyopathies. It is comparable to Solid's SGT-501 and preclinical cardiac programs (SGT-601/401/701) in target indication and modality.
  • 4D Molecular Therapeutics: 4D Molecular Therapeutics is a clinical-stage AAV gene therapy company that uses proprietary capsid engineering to develop targeted therapies for rare diseases including DMD and cardiac indications. Its Therapeutic Vector Evolution platform is comparable to Solid's POLARIS-101 capsid library.
  • Rocket Pharmaceuticals: Rocket Pharmaceuticals is a clinical-stage AAV gene therapy company developing treatments for rare diseases including Danon disease and LAD-I. It shares Solid's model of targeting ultra-rare monogenic diseases with AAV-delivered gene therapy and operates in a similar commercialization context via specialty treatment centers.

Broad incumbents

  • Pfizer: Pfizer is a large pharmaceutical company with a significant rare disease gene therapy franchise, including Beqvez (approved hemophilia B therapy) and a discontinued DMD gene therapy program. Its rare cardiovascular TA leadership also overlaps with Solid's cardiac focus, and Solid's CMO Gabriel Brooks joined from Pfizer.
  • BioMarin Pharmaceutical: BioMarin Pharmaceutical is an established rare disease biopharmaceutical company with a commercial gene therapy (Roctavian for hemophilia A) and an extensive rare disease portfolio. It is comparable to Solid in its focus on ultra-rare genetic disease therapeutics with premium pricing and specialty distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Solid Biosciences social profiles

Digital presence

Solid Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solid Biosciences leadership team

Management profile

Number of profiles

Profiles15 records

Solid Biosciences funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solid Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solid Biosciences

What does Solid Biosciences do?

Solid Biosciences is a clinical-stage precision genetic medicine company developing AAV gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (SGT-003), Friedreich's ataxia (SGT-212), and CPVT (SGT-501). The company leverages its proprietary POLARIS-101 (AAV-SLB101) next-generation capsid platform to deliver therapeutic genes and out-licenses the capsid technology to other gene therapy developers.

Is Solid Biosciences a public or private company?

Solid Biosciences is a public company. It is classified as public and is currently operating.

When was Solid Biosciences founded?

Solid Biosciences was founded in 2013. It employs 101 to 250 people.

Where is Solid Biosciences based?

Solid Biosciences is headquartered in Boston, United States, in the North America region.

How does Solid Biosciences make money?

Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are licensing and Technology Access.

Who are Solid Biosciences's main competitors?

Direct peers on record are Sarepta Therapeutics, Regenxbio, uniQure, Krystal Biotech, Lexeo Therapeutics, Tenaya Therapeutics, 4D Molecular Therapeutics and Rocket Pharmaceuticals. Broad incumbents are Pfizer and BioMarin Pharmaceutical.

Does Solid Biosciences have an API?

No public API is recorded for Solid Biosciences.

What industry is Solid Biosciences in?

Solid Biosciences's product category is Gene Therapy Biologics. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanSolid Biosciences to Speak at Jefferies Conference Nov. 16Solid Biosciences will participate in the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026. CEO Bo Cumbo will host a fireside chat at 2:30 p.m. GMT, with a live webcast and archived replay. Management will also hold investor one-on-one meetings.American Banking and Market NewsHC Wainwright Expects Higher Earnings for Solid BiosciencesHC Wainwright raised its FY2026 EPS estimate for Solid Biosciences to $1.60 from $1.63, keeping a Buy rating. The company reported Q4 2026 EPS of $0.36, beating the $0.41 consensus. Analysts' consensus target price is $20.00.Business & FinancialSolid Biosciences To Participate In The Guggenheim 3Rd Annual Healthcare Innovation ConferenceSolid Biosciences, a precision genetic medicine company, will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference. The company's pipeline includes gene therapy candidates for Duchenne muscular dystrophy, Friedreich's ataxia, and various cardiac diseases. It also develops genetic regulator libraries to advance gene therapy delivery.Stock TitanSolid Biosciences to Meet Investors at Nov. 9 ConferenceSolid Biosciences management will participate in one-on-one investor meetings at the Guggenheim Healthcare Innovation Conference in Boston on November 9, 2026. The company develops gene therapy candidates for neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia.Investing.comSolid Biosciences receives EU orphan designation for SGT-212Solid Biosciences received EU orphan designation for SGT-212, a gene therapy for Friedreich's ataxia, after a positive EMA opinion. Five participants in the Phase 1b FALCON trial received the drug with no serious adverse events as of October 5. The company expects to report initial clinical data in the first quarter of 2027.Stock TitanSolid Biosciences Gets EC Orphan Designation for SGT-212Solid Biosciences announced the European Commission granted orphan designation to SGT-212 for Friedreich's ataxia. Five participants have received the gene therapy in the Phase 1b FALCON trial with no treatment-related serious adverse events as of October 5, 2026. The company expects to report initial clinical data in Q1 2027.MarketBeatSolid Biosciences (SLDB) Expected to Announce Quarterly Earnings on MondaySolid Biosciences is expected to report Q3 2026 earnings on Monday, with analysts projecting a loss of $0.37 per share. The company previously beat estimates with a $0.38 loss, and analysts forecast a full-year loss of $1.66 per share. The stock opened at $5.92 with a market cap of $634.74 million.EIN PresswireSolid Biosciences To Present Research Across Gene Therapy Development, Delivery And Manufacturing At ESGCT 2026Solid Biosciences will present research on gene therapy development, delivery, and manufacturing at ESGCT 2026, covering SGT-003 for Duchenne muscular dystrophy and its POLARIS-101 capsid. The company's advanced manufacturing platform has optimized over 200 operating parameters for scalable production.YahooSolid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026Solid Biosciences announced seven abstracts accepted for poster presentation at the 33rd ESGCT Annual Congress in Hamburg, October 27-30, 2026. The abstracts cover SGT-003, its POLARIS-101 capsid, and rAAV manufacturing. The company is advancing its gene therapy pipeline for neuromuscular and cardiac diseases.Ticker ReportSolid Biosciences (NASDAQ:SLDB) Stock Lifted to Strong-Buy by UBS GroupUBS Group upgraded Solid Biosciences to a strong-buy rating in a research note released Wednesday. The stock traded down $0.21 to $5.53, with an average analyst rating of Moderate Buy and a consensus target price of $18.79. The company reported a loss of $0.38 per share for the quarter, beating the consensus estimate.